Vivos Therapeutics (VVOS) Accounts Payables (2019 - 2026)

Vivos Therapeutics (VVOS) has 8 years of Accounts Payables data on file, last reported at $2.0 million in Q1 2026.

• Accounts Payables for Q1 2026 came in at $2.0 million, up 65.51% year-over-year; the trailing twelve-month figure through Mar 2026 was $2.0 million (up 65.51% YoY), and the FY2025 annual result was $1.7 million, up 52.91% from the prior year.
• Accounts Payables climbed to $2.0 million in Q1 2026 per VVOS's latest filing, from $1.7 million in the prior quarter.
• Over five years, Accounts Payables peaked at $2.5 million in Q1 2024 and troughed at $644000.0 in Q3 2022.
• A 5-year average of $1.5 million and a median of $1.5 million in 2023 frame the typical range for Accounts Payables.
• The sharpest annual moves came in 2023 and 2025: Accounts Payables surged 137.27% in 2023, then sank 51.74% in 2025.
• A 5-year view of Accounts Payables shows it stood at $1.4 million in 2022, then surged by 52.02% to $2.1 million in 2023, then tumbled by 48.81% to $1.1 million in 2024, then surged by 52.91% to $1.7 million in 2025, then gained by 18.88% to $2.0 million in 2026.
• Business Quant data shows VVOS's Accounts Payables at $2.0 million in Q1 2026, $1.7 million in Q4 2025, and $2.1 million in Q3 2025.